Do analysts agree on SAGE Therapeutics (Sage) stock's price target?
According to analysts' consensus price target of $70.63, Sage Therapeutics has a forecasted upside of 81.4% from its current price of $38.93. Sage Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
What is the upside from SAGE Therapeutics stock?
According to analysts, Sage Therapeutics's stock has a predicted upside of 36.23% based on their 12-month price targets. What analysts cover Sage Therapeutics?
Who buys Sage stock?
SAGE stock was acquired by a variety of institutional investors in the last quarter, including Cooper Financial Group, and State of Alaska Department of Revenue. Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas.
What kind of company is SAGE Therapeutics?
Sage Therapeutics Inc. SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression;
Is Sage Therapeutics a good buy?
Sage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 6 buy ratings, 8 hold ratings, and no sell ratings.
Will Sage Therapeutics stock go up?
The 20 analysts offering 12-month price forecasts for SAGE Therapeutics Inc have a median target of 54.50, with a high estimate of 105.00 and a low estimate of 36.00. The median estimate represents a +59.22% increase from the last price of 34.23.
Is SAGE a buy now?
Out of 11 analysts, 2 (18.18%) are recommending SAGE as a Strong Buy, 2 (18.18%) are recommending SAGE as a Buy, 7 (63.64%) are recommending SAGE as a Hold, 0 (0%) are recommending SAGE as a Sell, and 0 (0%) are recommending SAGE as a Strong Sell. What is SAGE's earnings growth forecast for 2022-2024?
Why is SAGE stock dropping?
Case in point: Sage Therapeutics (SAGE) shares dropped 24% since Monday, after the company released disappointing late-stage results for zuranolone, the major depressive disorder (MDD) drug candidate the company is collaborating on with Biogen.
Is SAGE a buy Zacks?
The Zacks database contains over 10,000 stocks. All of those stocks are classified into three groups: Sector, M Industry and X Industry....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
When did SAGE Therapeutics go public?
July 18, 2014Sage Therapeutics is traded on the NASDAQ Global Market under the ticker symbol SAGE and its CUSIP number is 78667J 108. When did Sage Therapeutics go public? Sage Therapeutics' initial public offering (IPO) occurred on July 18, 2014.
Who is the CEO of Sage Therapeutics?
Barry E GreeneSage Therapeutics / CEO
Does Sage Therapeutics drug test?
Does Sage drug test? No it does not.
Should I buy or sell Sage Therapeutics stock right now?
17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently...
What is Sage Therapeutics' stock price forecast for 2022?
17 Wall Street analysts have issued twelve-month price objectives for Sage Therapeutics' stock. Their forecasts range from $37.00 to $85.00. On ave...
How has Sage Therapeutics' stock performed in 2022?
Sage Therapeutics' stock was trading at $42.54 on January 1st, 2022. Since then, SAGE shares have decreased by 18.7% and is now trading at $34.58....
When is Sage Therapeutics' next earnings date?
Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Sag...
How were Sage Therapeutics' earnings last quarter?
Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported ($2.07) EPS for the...
Who are Sage Therapeutics' key executives?
Sage Therapeutics' management team includes the following people: Mr. Barry E. Greene , Pres, CEO & Director (Age 59, Pay $1.25M) ( LinkedIn Pro...
Who are some of Sage Therapeutics' key competitors?
Some companies that are related to Sage Therapeutics include Grifols (GRFS) , Maravai LifeSciences (MRVI) , Legend Biotech (LEGN) , Sarepta The...
What other stocks do shareholders of Sage Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA) , A...
What is Sage Therapeutics' stock symbol?
Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."
When will Sage Therapeutics release its earnings?
How much does Sage Therapeutics make?
Sage Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021. View our earnings forecast for Sage Therapeutics.
Who bought Sage Therapeutics?
Sage Therapeutics has a market capitalization of $2.82 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $606.07 million in net income (profit) each year or ($9.47) on an earnings per share basis.
What is Sage Therapeutics?
Company insiders that have bought Sage Therapeutics stock in the last two years include Albert Robichaud, Barry E Greene, James M Frates, and Jeffrey M Jonas. View insider buying and selling activity for Sage Therapeutics or or view top insider-buying stocks.
Where is Sage Therapeutics located?
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company’s product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Sage Therapeutics (NASDAQ:SAGE) Price Target and Consensus Rating
and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Analyst Ratings By Month
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy).
Average Share Price and Price Target by Month
The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Sage Therapeutics (NASDAQ:SAGE) Analyst Ratings Frequently Asked Questions
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target.